TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34525734

Group type: EXPERIMENTAL
Intervention: Gradient Boosting Algorithm (GBM) for drought prediction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normalized Difference Water Index (NDWI‐7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Snow Cover Fraction (SCF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extremely Randomized Trees (ERT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta‐Gaussian model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extreme drought and hot conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extreme hot conditions
Number of subjects: 0
Study: 33885930

Group type: EXPERIMENTAL
Intervention: n-3 PUFA treatment for 24 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 142
Study: 34605142

Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Humalog
Number of subjects: 0
Study: 32049789

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rhubarb
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: UTI plus Rhubarb
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 33126317

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs) combined with traditional Chinese medicine (TCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 0
Study: 33751003

Group type: EXPERIMENTAL
Intervention: TRIOS 3
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CS 3600
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Emerald S
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Full metal crown
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-translucency substrate group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Polished and unpolished class II amalgam restorations
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All three scanners
Number of subjects: 11
Study: 34455218

Group type: EXPERIMENTAL
Intervention: Origanum majorana tea
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34786698

Group type: EXPERIMENTAL
Intervention: Digital voice recorder app
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reminder app
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Experimenter-assigned tasks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Digital recorder or reminder app usage
Number of subjects: 52
Study: 33561514

Group type: EXPERIMENTAL
Intervention: Personal relative deprivation (PRD) group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-PRD group
Number of subjects: 48
Study: 33184743

Group type: EXPERIMENTAL
Intervention: Psilocybin (0.143 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 35364250

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active-control
Number of subjects: 0
Study: 32332672

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (CACB) with 0.5% ropivacaine 20 mL followed by continuous infusion of 0.2% ropivacaine at 5 mL/h for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single‐injection adductor canal block (SACB) with 0.5% ropivacaine 20 mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (CACB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single‐injection adductor canal block (SACB)
Number of subjects: 60
Study: 34003071

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg capsule, 1 hour before)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (cellulose capsule, 1 hour before)
Number of subjects: 14
Study: 37941802

Group type: EXPERIMENTAL
Intervention: 10-µg/dose vaccine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 5-µg/dose vaccine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (adjuvant only)
Number of subjects: 135
Study: 33045915

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment using anthropometric measurements and WHO Anthro software
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Body mass index measurements of mothers
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Assessment of metabolic risk in mothers
Number of subjects: 408
Study: 32470515

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 36216204

Group type: EXPERIMENTAL
Intervention: Remimazolam (Group R)
Number of subjects: 40
Study: 32955164

Group type: EXPERIMENTAL
Intervention: 20 IU·kg bw−1 rhEpo injections every second day for 3 weeks during exposure at sea level
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 20 IU·kg bw−1 rhEpo injections every second day for 3 weeks during exposure at altitude
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo injections at sea level
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo injections at altitude
Number of subjects: 73
Study: 32933339

Group type: EXPERIMENTAL
Intervention: t‐year event rate
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: restricted mean survival time with fixed τ
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: generalized Wilcoxon, maximum of test statistics from multiple weighted log‐rank tests, difference in t‐year event rate, difference in restricted mean survival time with fixed and adaptive τ
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: various tests investigated
Number of subjects: 69
Study: 36229489

Group type: EXPERIMENTAL
Intervention: Birdsong high diversity soundscape
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Birdsong low diversity soundscape
Number of subjects: 295

Group type: COMPARATOR
Intervention: Traffic noise low diversity soundscape
Number of subjects: 295

Group type: COMPARATOR
Intervention: Traffic noise high diversity soundscape
Number of subjects: 295
Study: 33845615

Group type: EXPERIMENTAL
Intervention: Routine capsular closure
Number of subjects: 116

Group type: COMPARATOR
Intervention: Unrepaired capsulotomy (control group)
Number of subjects: 116
Study: 32379479

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous intensity interval exercise program (30 minutes, 3 days per week for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 36251544

Group type: EXPERIMENTAL
Intervention: SDF (17% Silver Diamine Fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDF-KI (Silver Diamine Fluoride with Potassium Iodide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RV-SDF (Riva Star)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RV-SDFKI (Riva Star with Potassium Iodide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SDF-KI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment groups (SDF, SDF-KI, RV-SDF, RV-SDFKI)
Number of subjects: 0
Study: 32938633

Group type: EXPERIMENTAL
Intervention: Opportunistic screening (pulse palpation, electronic blood pressure measurement with atrial fibrillation algorithm, ECG with handheld device)
Number of subjects: 18744

Group type: EXPERIMENTAL
Intervention: Opportunistic screening (12 lead ECG)
Number of subjects: 18744

Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 18744

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18744
Study: 33287617

Group type: EXPERIMENTAL
Intervention: Physical stressor (4 × 6‐s bike sprints) on D14
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychological stressor (5 × 2‐min cognitive tests with social evaluation) on D14
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physical stressor on D7
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physical stressor on D21
Number of subjects: 30

Group type: COMPARATOR
Intervention: Psychological stressor on D7
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychological stressor on D14
Number of subjects: 30

Group type: COMPARATOR
Intervention: Psychological stressor on D21
Number of subjects: 30
Study: 33130414

Group type: COMPARATOR
Intervention: Higher school-level value-added education (VAE)
Number of subjects: 3337

Group type: COMPARATOR
Intervention: Higher overall levels of commitment and belonging
Number of subjects: 3337

Group type: COMPARATOR
Intervention: Stronger personal commitment to learning and teacher relationships
Number of subjects: 3337

Group type: COMPARATOR
Intervention: Participation and contraception use
Number of subjects: 3337
Study: 34405256

Group type: EXPERIMENTAL
Intervention: 6-day subcutaneous GIP infusion (6 pmol kg-1 min-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline [154 mmol/l NaCl])
Number of subjects: 20
Study: 33177712

Group type: EXPERIMENTAL
Intervention: Bread intervention
Number of subjects: 491
Study: 34954841

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg 2 ml autoinjector (AI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 2× 1 ml prefilled syringe (PFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg 2 ml AI
Number of subjects: 0
Study: 33551234

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 71
Study: 35306231

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) after multiagent chemotherapy (MA‐CTX)
Number of subjects: 44
Study: 32314472

Group type: EXPERIMENTAL
Intervention: Partial replacement concentrate Ⅱ (PRC II, 50% corn + 22.5% cassava residue + 22.5% DDGS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Typical concentrate (TC, 65% corn + 15% wheat bran + 15% soybean meal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Partial replacement concentrate Ⅰ (PRC I, 50% corn + 22.5% corn gluten + 22.5% PKC)
Number of subjects: 30
Study: 36007339

Group type: COMPARATOR
Intervention: Satralizumab in combination with baseline immunosuppressive therapy (IST)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Satralizumab monotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 75
Study: 34478788

Group type: EXPERIMENTAL
Intervention: Potassium nitrate in polycarboxylate cement
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 48
Study: 32933571

Group type: EXPERIMENTAL
Intervention: Graded activity and pain education (GAPE)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 144
Study: 34645366

Group type: EXPERIMENTAL
Intervention: BFR group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BFR + MI group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 32524338

Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 51

Group type: COMPARATOR
Intervention: RTX originator
Number of subjects: 51
Study: 35682148

Group type: EXPERIMENTAL
Intervention: Copenhagen adduction exercise (CAE) for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 45
Study: 32813947

Group type: EXPERIMENTAL
Intervention: Evinacumab (15 mg/kg every 4 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Evinacumab
Number of subjects: 65
Study: 32969535

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Habitual diet (HD)
Number of subjects: 8
Study: 34378320

Group type: EXPERIMENTAL
Intervention: App group (10 min app-guided mindfulness for 4 weeks)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Wait to Treat group (received the same intervention after initial wait)
Number of subjects: 148
Study: 34334440

Group type: EXPERIMENTAL
Intervention: Teenage workers (both genders)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 2800
Study: 32682397

Group type: EXPERIMENTAL
Intervention: Low Fio2 (0.4)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High Fio2 (1.0)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intra- and postoperative Pao2 to Fio2 ratio
Number of subjects: 90

Group type: COMPARATOR
Intervention: Postoperative pulmonary complications
Number of subjects: 90
Study: 35354325

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy treatments
Number of subjects: 665
Study: 33957878

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Boys in both groups
Number of subjects: 180
Study: 32776173

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 20 min)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28
Study: 35465275

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g 30-60 min before incision (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cefazolin 2 g 30-60 min before incision and Tinidazole 1.6 g 60-120 min before incision (Group B)
Number of subjects: 200
Study: 34106582

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural play therapy (CBPT)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 178
Study: 36339275

Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment of omega-3 fatty acids and inositol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study: 32246106

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON) group for 8 weeks
Number of subjects: 30
Study: 34080238

Group type: EXPERIMENTAL
Intervention: Intraoral optical scanning (IOS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional impressions (polyether)
Number of subjects: 32
Study: 35324094

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50‐300 mg/d
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 32743900

Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Terror news (Muslims attacking non-Muslims)
Number of subjects: 358
Study: 34116394

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (1000 IU/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 44
Study: 33404048

Group type: EXPERIMENTAL
Intervention: hJAM (hierarchical joint analysis model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hJAM
Number of subjects: 0
Study: 35750013

Group type: EXPERIMENTAL
Intervention: Comic-based intervention
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Lessons-as-usual (control)
Number of subjects: 2400
Study: 32070779

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 967

Group type: COMPARATOR
Intervention: Supraglottic airway (SGA) insertion
Number of subjects: 967
Study: 32227431

Group type: EXPERIMENTAL
Intervention: Revised decoupling protocol
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional decoupling and HRT
Number of subjects: 1
Study: 35838110

Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanate potassium suspension (200 mg/28.5 mg) under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanate potassium suspension (200 mg/28.5 mg) under postprandial conditions
Number of subjects: 24
Study: 33001268

Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) conversations
Number of subjects: 15
Study: 33920994

Group type: EXPERIMENTAL
Intervention: Chemical pesticide use; 84% of farmers used exclusively chemical pesticides.
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Unsafe practices of pesticide handling; farmers with unsafe practices were two times more likely to suffer from acute poisoning.
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Perception/attitude towards chemical pesticide policy and market management; significantly associated with safe practices.
Number of subjects: 790
Study: 32970396

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4304
Study: 35710247

Group type: EXPERIMENTAL
Intervention: Nurse or allied health professional-led follow-up appointment 4 weeks after TIA/minor stroke, including a needs checklist, action plan, resources, GP letter, and training.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 35672161

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SCB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clearfil SE Bond (B; negative control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ESPE Sil (S)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clearfil Ceramic Primer Plus (CPP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clearfil Repair (CR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diamond bur (D)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Airborne abrasion (A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating (T)
Number of subjects: 15
Study: 34284783

Group type: EXPERIMENTAL
Intervention: Participatory patient care plan
Number of subjects: 605

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 605
Study: 32406728

Group type: EXPERIMENTAL
Intervention: Positive Physical Activity (PPA) intervention
Number of subjects: 1983
Study: 34738192

Group type: EXPERIMENTAL
Intervention: Teaspoon labelling
Number of subjects: 563

Group type: COMPARATOR
Intervention: Plain labelling
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: 20% increase in SSB prices
Number of subjects: 563
Study: 33580923

Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.005% ophthalmic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical betamethasone diproprionate 0.05% lotion
Number of subjects: 50
Study: 34672899

Group type: EXPERIMENTAL
Intervention: Counseling + Recreational Physical Activity Group (CPAG)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Counseling Group (CG)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both interventions (CG and CPAG)
Number of subjects: 74
Study: 33386947

Group type: EXPERIMENTAL
Intervention: mirabegron
Number of subjects: 91

Group type: COMPARATOR
Intervention: anticholinergics
Number of subjects: 91
Study: 35262625

Group type: EXPERIMENTAL
Intervention: Prasugrel dose de-escalation (5 mg daily) at 1 month post-PCI
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Conventional therapy (10 mg daily)
Number of subjects: 2271
Study: 33729570

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology (FNAC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fine needle non-aspiration cytology (FNNAC)
Number of subjects: 104
Study: 32019599

Group type: EXPERIMENTAL
Intervention: HO‐1‐transfected UCMSCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anisomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: shHO‐1 transfected UCMSCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: SP600125
Number of subjects: 0
Study: 33987879

Group type: EXPERIMENTAL
Intervention: Training cohort with bladder neck position on Valsalva, Vectors 3, and BMI
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Funneling and Vector 3
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Predictive model incorporating funneling, Vectors 3, and BMI
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hiatal area (HA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mid-urethral mobility
Number of subjects: 300
Study: 34165199

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34997899

Group type: EXPERIMENTAL
Intervention: Internet-Delivered Acceptance and Commitment Therapy (iACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control condition (iFORUM)
Number of subjects: 0
Study: 33618197

Group type: EXPERIMENTAL
Intervention: Late-onset regular tobacco smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early-onset regular tobacco smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early-onset regular cannabis users
Number of subjects: 0
Study: 32202510

Group type: EXPERIMENTAL
Intervention: PI-mono (ritonavir-boosted protease inhibitors)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 85
Study: 35441486

Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Number of subjects: 171

Group type: COMPARATOR
Intervention: High-flux dialyzer
Number of subjects: 171
Study: 35010881

Group type: EXPERIMENTAL
Intervention: Salt Control H equipment used to monitor and control salt during cooking for 8 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 35318869

Group type: EXPERIMENTAL
Intervention: ASSIP (Attempted Suicide Short Intervention Program)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Crisis Counselling (CC)
Number of subjects: 239
Study: 34405305

Group type: EXPERIMENTAL
Intervention: Opioid antagonist naltrexone (50 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 84
Study: 34237249

Group type: EXPERIMENTAL
Intervention: SBRT plus pembrolizumab and trametinib
Number of subjects: 170

Group type: COMPARATOR
Intervention: SBRT plus gemcitabine
Number of subjects: 170
Study: 32274491

Group type: EXPERIMENTAL
Intervention: Single low level laser therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35639947

Group type: EXPERIMENTAL
Intervention: No dressing (intervention group)
Number of subjects: 754

Group type: COMPARATOR
Intervention: Tamponade dressing (control group)
Number of subjects: 754
Study: 34109364

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam + Fentanyl (0.02 mg/kg midazolam and 2.0 μg/kg fentanyl)
Number of subjects: 50
Study: 33308259

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (ND)
Number of subjects: 16